6th HIV & Women presentations

 Session 1: Prevention in Women
  HIV prevention and reproductive choices
Dr. R. Heffron
  Prevention in young women
Dr. S. Delany-Moretlwe
  Female condom, diaphragms, cervical caps and other barrier methods
Dr. J. Schwartz
 Round Table Discussion: What are the next steps in Prevention
  Long-acting antiretroviral prevention (injectables, rings, etc.)
Dr. S. Hillier
 Session 2: Women living with HIV
  Trans women _ research issues
Dr. J. Lama
  Trans women _ real life experience
Dr. Y. Persad
  Exploring contexts of HIV vulnerability and protective factors among young transgender women in Kingston, Jamaica
Dr. C. Logie
  Social drivers of HIV vulnerability among lesbian, bisexual, queer and transgender women in Swaziland
Dr. C. Logie
 Session 3: Abstract driven presentations
 Comparison of Adherence Measures in a Phase 1 Clinical Trial of PC-1005 Vaginal Gel
Dr. B. Friedman
  Reduced activation of emtricitabine and tenofovir in cervical and vaginal explants from post-menopausal donors
Dr. M. Nicol
  Use of HIV pre-exposure prophylaxis during conception, pregnancy and lactation at 2 U.S. medical centers
Dr. D. Seidman
 Use of injectable hormonal contraception independently predicts HSV-2 acquisition in a cohort of street- and off-street sex workers in Vancouver, Canada
Dr. J. Chettiar
  Strategies to improve the uptake of effective contraception in HIV-positive adolescents
Dr. N. Kancheva Landolt
 Session 4: Treatment - Current ARV in women
  When to start / When not to start
Dr. AM Geretti
  The management of the HIV positive pregnant woman: the UK perspective
Dr. A. de Ruiter
  Does delivery after 40 weeks gestation increase maternal to child transmission of HIV in well controlled HIV-infected pregnant women? A prospective cohort study
Dr. R. Scott
  PK of FTC, TFV and 3TC in Ugandan and Nigerian breastfeeding mother-infant pairs
Dr. S. Nakalema
 Session 5: Abstract driven presentations
  Treatments and co-morbidities in German female HIV-infected patients in 2015 - a comparison to 2008
Dr. S. Usadel
 Patient characteristics, duration on antiretrovirals (ARVs) and adherence in an insured US population receiving ARVs in 2010-2014: a focus on women
Dr. J. Forlenza
  mHealth to improve health: a weekly text messaging intervention to improve ART adherence and HIV viral load in a Canadian context: WelTel OAKTREE
Dr. K.Friesen
  The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
Dr. I. Boucoiran
  Viral suppression and retention in care 2-5 years after ART initiation in pregnancy in Uganda
Dr. C. Koss
 Session 6: Treatment - Contnuum of Care
  Gender, socio-economic status and HIV-treatment outcomes
Dr. F. Lampe
  The promise and challenges of universal ART for women in South Africa: Option B+ and beyond
Dr. L. Myer
 Factors influencing Lost to Follow-up in a Prevention of Mother-To-Child Transmission (PMTCT) Program in Northern Nigeria
Dr. F. Oluwasina
  Retention overtime and reasons for discontinuation of lifelong ART in a group of Cameroonian pregnant and breastfeeding HIV-positive women initiating "Option B+"
Dr. P. Atanga
 Session 7: Co-infection issues
  Young women of child bearing age presenting with MDR TB
Dr. F. Conradie
  Co-infection with hepatitis C in women
Dr. A. Kim
  The Hepatitis C cascade of care in a women-centered HIV clinic in Canada
Dr. A. Mah